Cargando…
Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
Autor principal: | Busato, Wilson F. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Urologia
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088470/ https://www.ncbi.nlm.nih.gov/pubmed/32167713 http://dx.doi.org/10.1590/S1677-5538.IBJU.2020.03.02 |
Ejemplares similares
-
Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update)
por: Zhu, Yao, et al.
Publicado: (2020) -
Recommendations for prostate cancer diagnosis and treatment during COVID-19 outbreak were not followed in Brazil
por: Korkes, Fernando, et al.
Publicado: (2022) -
Prostate cancer mortality and costs of prostate surgical procedures in the Brazilian public health system
por: Porcacchia, Allan Saj, et al.
Publicado: (2022) -
Prostate specific membrane antigen (PSMA) and Prostate Cancer Staging: is our current conventional staging obsolete?
por: Céspedes, Melissa Segura, et al.
Publicado: (2021) -
Α 78-year-old female who presents with a non-resolving pneumonia: what is your diagnosis?
por: Panagiotidou, Evangelia, et al.
Publicado: (2018)